TB-500 is the active fragment of thymosin beta-4 (Tβ4), the 43-amino-acid protein sitting in basically every nucleated cell you have (Goldstein et al., Ann N Y Acad Sci, 2005). Unlike a lot of research peptides where the origin story is murky, TB4 has decades of basic science behind it. TB-500 strips that protein down to amino acids 17–23 (LKKTETQ), the G-actin-binding stretch that does most of the cytoskeletal work (Van Troys et al., EMBO J, 1996).
Key Takeaways
- —TB-500 is a synthetic fragment of thymosin beta-4, a protein present in all nucleated human cells and critically involved in actin regulation.
- —Key mechanisms: actin sequestration, anti-inflammatory cytokine modulation, and promotion of cell migration — all relevant to tissue repair.
- —Research has demonstrated cardiac regeneration effects in animal infarction models; a phase II trial in cardiac surgery patients is in progress.
- —Common research protocols: 2–5 mg twice weekly for 4–6 weeks (loading), followed by 2 mg monthly maintenance.
- —No FDA approval; used in research settings only.
TB4 exists because almost every cell in your body needs to manage actin, and TB4 is the protein doing it. It was first pulled out of thymic tissue in the 1960s and turns out to be one of the most abundant intracellular proteins in mammals — up to 0.01% of total cellular protein, with the highest concentrations in platelets, white blood cells, and connective tissue (Goldstein et al., Ann N Y Acad Sci, 2005). Its day job is actin sequestration: it binds G-actin monomers and controls how much is available to polymerise into F-actin filaments (Safer et al., J Biol Chem, 1991). That makes TB4 a master regulator of the cytoskeleton — the internal scaffolding behind cell shape, migration, and division.
TB-500 is the slice researchers think does the heavy lifting on the regenerative and anti-inflammatory side. Running the active fragment instead of the full protein is just easier in practice: cleaner synthesis, better stability, simpler PK.
The actin-to-healing link is direct: wounds close because cells crawl toward the injury, and crawling needs cytoskeletal reorganisation. By controlling G-actin availability, TB-500 speeds up migration of keratinocytes, endothelial cells, and fibroblasts — the three cell types that do most of the wound-repair work.
In corneal wound models, topical TB4 hammered epithelial closure times down (Sosne et al., Exp Eye Res, 2002). That line of work eventually pushed an ophthalmic formulation into a phase III trial — one of the very few places thymosin beta-4 has actually entered formal human studies (Sosne et al., Ann N Y Acad Sci, 2015).
TB-500 dials down pro-inflammatory cytokines — IL-1β, TNF-α, NF-κB signalling — in injury and ischaemia models. The N-terminal LKKTNT hexapeptide of TB4 directly suppresses NF-κB activation, and that anti-inflammatory hit is independent of actin binding (Sosne et al., FASEB J, 2007). This isn't NSAID-style blunt suppression. It's more like modulating the resolution phase: shortening the acute inflammatory window that, when it drags on, actively blocks healing instead of helping it.
The cardiac story is the strongest piece of TB-500 research, full stop. In rat MI models, systemic TB4 kept cardiomyocytes alive, shrank infarct size, and pulled epicardial progenitor cells toward the injury — that last part suggests actual regeneration, not just cytoprotection (Smart et al., Nature, 2011).
That work fed into a phase II trial in CABG patients (RegeneRx TB4-002), which is one of the only real human trials in the TB4 space. Full results haven't been published as of 2026, but the preliminary readouts pointed to safety and tolerability (Crockford et al., Ann N Y Acad Sci, 2010).
Thymosin beta-4 appears to promote migration of epicardial progenitor cells and reactivate a developmental program involved in cardiac repair after ischaemic injury — a mechanism not replicated by any currently approved therapeutic ([PMC literature, 2024]). If translated to humans, this could represent a fundamentally new approach to post-MI recovery.
These two get stacked together constantly — the so-called Wolverine stack — and it helps to be clear on what each one is doing.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Origin | Thymosin beta-4 fragment | Gastric protein fragment |
| Primary mechanism | Actin regulation, cell migration | GH receptor upregulation, angiogenesis |
| Tissue preference | Connective tissue, cardiac, corneal | Musculoskeletal, GI, CNS |
| Half-life | Longer (hours, not sub-30 min) | <30 minutes |
| Human trials | Phase II cardiac trial | Only small pilot studies |
| Anti-inflammatory | Yes — cytokine modulation | Yes — via different pathways |
They don't overlap, which is why they stack. The hypothesis behind running them together for musculoskeletal work: BPC-157 drives angiogenesis (new vessels into the area), TB-500 drives cell migration (cells actually showing up to do the repair). Some people extend the stack to GLOW/KLOW (BPC + TB-500 + GHK-Cu + KPV) when skin and connective tissue are both in play.
Real human dosing data is thin. The protocols below come from the cardiac trial precedent (which used full-length TB4, scaled pharmacokinetically to TB-500) and from clinical practitioner reports.
BPC-157 is the one you usually want pinned near the site. TB-500 is different — its mechanism is cell migration, and migrating cells can find the injury from systemic circulation, so a regular subq pin in the belly is generally fine. Plenty of protocols still go local anyway, on the logic that higher local concentration won't hurt and might pull things along faster. Near the site, not in the joint, is the usual rule.
TB-500 has no FDA approval for any therapeutic use. It's not a controlled substance in the US. WADA bans it in competitive sport.
Human safety data is limited but nothing scary has surfaced. The TB4 cardiac trial reported acceptable tolerability. Animal work hasn't flagged significant toxicity. The theoretical concerns worth knowing:
The TB-500 research profile on Next Pep covers the full actin-sequestration mechanism, the ongoing Phase II cardiac trial, pharmacokinetics, dosing tables, and the molecular weight distinction that trips people up (fragment 17–23 = ~889 Da vs full-length TB4 = 4,963 Da) — all in one cross-referenced view. That's the baseline before you evaluate any vendor claiming to sell TB-500.
If you're running TB-500 alongside BPC-157 — the Wolverine stack, easily the most common pairing in connective-tissue work — the comparison tool puts both compounds side-by-side across mechanism, half-life, FDA status, and human trial data. Once you've got a protocol, the dosing calculator handles BAC water reconstitution: enter vial mg and target dose, get exact draw volume and syringe units.
Next Pep's peptide library covers every major research peptide in the same data structure, so you're not relying on a vendor product page to make research decisions.
TB-500 gets researched for soft-tissue repair (tendons, ligaments, muscle), anti-inflammatory work, and cardiac recovery — that last one is the strongest evidence base. Most of the data is preclinical. The phase II cardiac surgery trial is the most advanced human research as of 2026.
Animal data and clinical reports point to 2–4 weeks for initial pain and inflammation effects; structural tissue changes generally need 4–8 weeks of loading. There's no peer-reviewed human efficacy trial that nails down a time-to-effect window, so anything more specific is anecdote.
Yes — that's the Wolverine stack and it's the standard combo in research protocols. Mechanisms don't overlap: BPC-157 drives angiogenesis and GH receptor upregulation, TB-500 drives cell migration via actin regulation. No known interaction or contraindication, though the combination hasn't been formally studied.
Not quite. TB-500 is the synthetic fragment matching amino acids 17–23 of TB4 (the LKKTETQ sequence), the stretch thought to do most of TB4's regenerative work (Van Troys et al., EMBO J, 1996). Full-length TB4 is what was used in the cardiac phase II trial. TB-500 is what shows up in research peptide contexts.
This article is for research and informational purposes only. TB-500 is not approved for human therapeutic use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.